SCHEDULE 13G/A: Rubric Capital Management LP and David Rosen Disclose 4.71% Passive Stake in Trevi Therapeutics
Beneficial Ownership Report
Rubric Capital Management LP and David Rosen have filed an amended Schedule 13G, reporting a 4.71% beneficial ownership stake in Trevi Therapeutics, Inc. as of December 31, 2024.
Summary
- Rubric Capital Management LP and David Rosen collectively reported beneficial ownership of 4,205,129 shares of Trevi Therapeutics, Inc. Common Stock.
- This ownership represents 4.71% of the outstanding Common Stock of Trevi Therapeutics, Inc.
- The percentage is calculated based on 89,365,711 shares outstanding as of December 17, 2024.
- The outstanding share count includes 76,865,711 shares as of October 31, 2024, and an additional 12,500,000 shares issued on December 17, 2024.
- The Reporting Persons, Rubric Capital Management LP and David Rosen, share both voting and dispositive power over all 4,205,129 shares.
- The shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: The document is a neutral, factual disclosure of beneficial ownership, providing no explicit positive or negative sentiment regarding the company's performance or prospects.
Positives
- The document is a factual disclosure of beneficial ownership and does not contain explicit positive statements regarding the company's performance or outlook.
Negatives
- The document is a factual disclosure of beneficial ownership and does not contain explicit negative statements regarding the company's performance or outlook.
Future Outlook
This Schedule 13G filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding the issuer's future outlook.
Industry Context
This filing is a routine disclosure of an institutional investor's passive ownership stake in a publicly traded biotechnology or pharmaceutical company, common in the financial industry for transparency regarding significant holdings.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's passive stake, which may offer some level of confidence or insight into institutional interest.
Key Dates
| Date | Description |
|---|---|
| 2024-10-31 | Date of outstanding shares reported in Issuer's Quarterly Report on Form 10-Q (76,865,711 shares). |
| 2024-12-17 | Date of issuance of 12,500,000 additional shares of Common Stock by the Issuer. |
| 2024-12-31 | Date of event which requires filing of this statement (beneficial ownership calculation date). |
| 2025-02-13 | Date of signing of the Schedule 13G Amendment No. 3. |
Keywords
Trevi Therapeutics, Rubric Capital Management, David Rosen, Beneficial Ownership, Schedule 13G, SEC Filing, Common Stock, Investment Adviser, Passive Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.